Find any stock by ticker or company name
Barcha huquqlar himoyalangan.
1.58
-0.14 (-7.89%)
Spectral AI, Inc. (MDAI) Q2 2026 Earnings Call Transcript
Spectral AI NASDAQ: MDAI said its second-quarter results marked a transition toward commercial operations following the U.S. Food and Drug Administration's De Novo clearance of its DeepView System for burn assessment in May. The company reiterated its 2026 revenue guidance of approximately $18.5 million, which does not assume significant revenue from DeepView system sales.
Company Continues to Advance Towards First Commercial Sales of the DeepView® System for Burn Indication Strong Cash Position of $14.0 Million at June 30, 2026 DALLAS, Aug. 11, 2026 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (Nasdaq: MDAI) (“Spectral AI” or the “Company”), an artificial intelligence company focused on medical diagnostics for faster and more accurate treatment decisions in wound care, today announced financial results for the second quarter ended June 30, 2026 (“Q2 2026”). “Spectral AI has entered the second half of 2026 with tremendous momentum and a clear sense of purpose,” said Vincent Capone, Chief Executive Officer of Spectral AI.
There is no data to display
